RNAi drug specialist ADARx raises $446M IPO

AI Summary

ADARx, a company specializing in RNA interference drugs, raised $446 million through an IPO, marking the first RNAi biotech public offering in the U.S. since 2024. This highlights significant investor interest in RNA-based pharmaceutical technologies.

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.